August 6, 2020 07:32 AM EDTUpdated 10:06 AM

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remdesivir; Hahn pleads with public to trust FDA's vaccine review

ENDPOINTS

A bipartisan group of 34 attorneys general have asked the federal government to bypass Gilead’s patent rights on remdesivir and begin scaling and distributing the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remdesivir; Hahn pleads with public to trust FDA's vaccine review

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

FDA rejects Savara’s rare lung disease drug over limited manufacturing data

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine re­view

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remdesivir; Hahn pleads with public to trust FDA's vaccine review